{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-007655","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.992014+00:00","generated_at":"2026-05-16T11:17:54.333820+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anika Therapeutics appoints Steve Griffin CEO effective Feb 1, 2026; Cheryl Blanchard becomes Executive Chair","bullets":["Steve Griffin, current CFO & COO, promoted to President and CEO effective Feb 1, 2026.","Cheryl Blanchard transitions from CEO to Executive Chair for 12 months, then Special Advisor.","Reaffirmed FY2025 guidance: Commercial Channel $47-49.5M (+12-18% YoY), OEM $62-65M (-16-20% YoY).","Director Susan Vogt resigns effective Feb 1, 2026; no disagreements with the Company.","Griffin receives $690k base salary, 75% target bonus, and $2.45M equity grant vesting over three years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-007655","json":"https://secwatch.observer/filing/0001193125-26-007655.json","markdown":"https://secwatch.observer/filing/0001193125-26-007655.md","text":"https://secwatch.observer/filing/0001193125-26-007655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000119312526007655/0001193125-26-007655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000119312526007655/d136217d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:17:54.333820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}